CompletedNot Applicable

Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).

Pakistan1,206 participantsStarted 2020-07-31

Plain-language summary

An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Pulmonary health has been the main focus of studies of COVID-19, current articles show that cutaneous signs appear in COVID-19 patients, their identification may be vital to early diagnosis and lead to possible better prognosis in COVID-19 patients

Who can participate

Age range

20 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: both genders Any age PCR diagnosed COVID-19 patient irrespective of symptoms Exclusion Criteria: patient with diagnosed case of autoimmune disease on drugs known case of malignancy or chemotherapy recurrent transfusion history diagnosed case of malabsorption syndrome On immunosuppressant. Already having any prior skin disease Any drug/vaccine taken within 14 days before onset of rash Pregnant or lactating women.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Frequency of skin manifestations in 1206

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

COVID-19 Disease Outcome in patients with skin manifestations

Timeframe: Disease outcome during this 12 months duration of study.

Cutaneous patterns

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

Association of COVID-19 disease outcome in correlation with skin manifestation

Timeframe: From day of randomisation until development of skin manifestations or not, until COVID-19 disease outcome (improved, worsen or death) assessed upto 12 months

Skin symptoms

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

Duration of skin manifestations

Timeframe: From day of randomisation until development of skin manifestation or not, if development/already developed skin manifestations then resolution of it or for how long it persisted, assessed upto 12 months

Trial details

NCT IDNCT05094687

SponsorJinnah Postgraduate Medical Centre

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2021-08-01

View on ClinicalTrials.gov More Cutaneous Manifestations trials

Plain-language summary

Who can participate

Age range

20 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Frequency of skin manifestations in 1206

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

COVID-19 Disease Outcome in patients with skin manifestations

Timeframe: Disease outcome during this 12 months duration of study.

Cutaneous patterns

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

Association of COVID-19 disease outcome in correlation with skin manifestation

Timeframe: From day of randomisation until development of skin manifestations or not, until COVID-19 disease outcome (improved, worsen or death) assessed upto 12 months

Skin symptoms

Timeframe: From day of randomisation until development of skin manifestations or not, assessed upto 12 months

Duration of skin manifestations